Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16605160 | 0.89 | FFAR1 (0.47) | FFAR1FFAR4PTGER4PTGER3PTGER1 | |
| SCHEMBL35843129 | 0.89 | MTNR1A (0.44) | FFAR1FFAR4MTNR1AMTNR1BPPARG | |
| SCHEMBL1903298 | 0.89 | MTNR1A (0.44) | FFAR1FFAR4MTNR1AMTNR1BPPARG | |
| SCHEMBL1888760 | 0.87 | AKR1C3 (0.45) | FFAR1FFAR4MTNR1AMTNR1BPOLB | |
| SCHEMBL1892518 | 0.86 | FFAR1 (0.47) | FFAR1FFAR4PTGER4PTGER3PTGER1 | |
| SCHEMBL1887137 | 0.86 | FFAR1 (0.53) | FFAR1FFAR4MTNR1AMTNR1BPOLB | |
| SCHEMBL1889009 | 0.86 | FFAR1 (0.54) | FFAR1FFAR4MTNR1AMTNR1BPOLB | |
| SCHEMBL1804925 | 0.86 | CYP11B2 (0.45) | FFAR1FFAR4MTNR1AMTNR1BPOLB | |
| SCHEMBL17254706 | 0.86 | FFAR1 (0.54) | FFAR1FFAR4MTNR1AMTNR1BPOLB | |
| SCHEMBL1886592 | 0.85 | FFAR1 (0.53) | FFAR1FFAR4MTNR1AMTNR1BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160184274-A1 | Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition | UNIVERSITAT DE VALENCIA (ES) | 2016-06-30 | — | — | US | claimed |
| EP-2496544-B1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | FIBROSTATIN S L (SE) | 2014-08-20 | — | — | EP | claimed |
| US-8586776-B2 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2013-11-19 | — | — | US | claimed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | claimed |
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | UNIVERSITAT DE VALÈNCIA (ES) | 2020-01-28 | — | — | US | disclosed |
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | UNIVERSITAT DE VALÈNCIA (ES) | 2020-01-28 | — | — | US | disclosed |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2018-06-28 | — | — | US | disclosed |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2018-06-28 | — | — | US | disclosed |
| US-20160184274-A1 | Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition | UNIVERSITAT DE VALENCIA (ES) | 2016-06-30 | — | — | US | disclosed |
| US-20160083327-A1 | GPBP inhibition using Q2 peptidomimetics | JUAN SAUS (ES) | 2016-03-24 | — | — | US | disclosed |
| US-20160083327-A1 | GPBP inhibition using Q2 peptidomimetics | JUAN SAUS (ES) | 2016-03-24 | — | — | US | disclosed |
| US-20160083327-A1 | GPBP inhibition using Q2 peptidomimetics | JUAN SAUS (ES) | 2016-03-24 | — | — | US | disclosed |
| US-20140080852-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2014-03-20 | — | — | US | disclosed |
| US-20140080852-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2014-03-20 | — | — | US | disclosed |
| US-8586776-B2 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2013-11-19 | — | — | US | disclosed |
| US-8586776-B2 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2013-11-19 | — | — | US | disclosed |
| WO-2011054530-A1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | FIBROSTATIN, S.L. (ES) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | FFAR1 2951/4885FFAR4 2889/4885MTNR1A 4363/4885 |
| US-20140080852-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | FFAR1 2951/4885FFAR4 2889/4885MTNR1A 4363/4885 |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | FFAR1 2951/4885FFAR4 2889/4885MTNR1A 4363/4885 |
| US-20160184274-A1 | Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition | VIM, EPCAM, CDH1 | FFAR1 4443/4885FFAR4 4492/4885MTNR1A 2268/4885 |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | FFAR1 2951/4885FFAR4 2889/4885MTNR1A 4363/4885 |
| US-20160083327-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | FFAR1 2951/4885FFAR4 2889/4885MTNR1A 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.